General Proximity
Foundation model
Proximity-medicine platform (OmniTAC effectome discovery engine) for undruggable targets; Daiichi Sankyo collaboration, YC-backed.
General Proximity builds next-generation 'proximity medicines' — therapeutics that control biology through proximity principles (targeted protein degradation / induced-proximity). Its OmniTAC platform is a generalized, mechanism-agnostic discovery engine built on the 'effectome' (the full set of effector proteins), aimed at historically undruggable targets.
Research mapping
Healthspan / Intervene (AI) / Foundation model
Evidence boundary
Original analysis and independent corroboration remain under development. Commercial scale and durable technical advantage remain under review.
What makes it defensible
First generalized, mechanism-agnostic proximity discovery engine (effectome) — reframes TPD from single degraders to a platform.
Position in the stack: Discovery-engine layer: pharma partners license/co-develop against undruggable targets (Daiichi Sankyo oncology collaboration; J&J/JLabs; ARPA-H + NCI grants).
Who buys it
Named customers: Daiichi Sankyo
Founding team
Armand Cognetta — Co-founder & CEO — Chemical biology / small-molecule drug discovery
SourceFinancing detail
- Last round
- Series A
Investors: Gideon; Felicis Ventures; Y Combinator; Freemind; age1
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
Evidence & media
-
General Proximity de-stealths with $16M for induced-proximity medicines
What this source supports: $8M seed led by Felicis (Aydin Senkut) plus a pre-seed led by Y Combinator and Jim Dahl (Rock Creek); OmniTAC induced-proximity platform; ARPA-H and NCI non-dilutive grants; >$250B/yr addressable market claimed.
What it does not establish: Company release — no IND, lead asset, or clinical data.
Source -
FreeMind Investments and Daewoong Pharmaceutical invest in General Proximity
What this source supports: Strategic investment from FreeMind Investments and Daewoong Pharmaceutical (an oversubscribed $12M pre-Series A per Dealroom).
What it does not establish: Company post — amount and terms not stated in the post itself.
Source -
Dealroom: General Proximity Bio raises $28M across seed and pre-Series A
What this source supports: $28M across seed plus an oversubscribed $12M pre-Series A (Daewoong Pharmaceutical, FreeMind Investments); still preclinical with no public IND or lead asset.
What it does not establish: Aggregated news feed — no clinical or revenue data.
Source
Timeline
-
Financing
Series A
Source